Navigation Links
Immune Pharmaceuticals Completes Merger with EpiCept Corporation
Date:8/25/2013

TARRYTOWN, N.Y., Aug. 26, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (Nasdaq OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) (the "Company") announced today the completion of the merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation.  The merger combines Immune's antibody therapeutic platform focused on the treatment of inflammatory diseases and cancer with EpiCept's early stage cancer program and its late-stage topical pain product, AmiKet™.

Daniel G. Teper, the Company's Chairman and Chief Executive Officer, commented, "It is very gratifying to witness the culmination of our work over the past several months. Not only have we successfully completed our merger with EpiCept, but our common stock has also commenced trading in the United States and Sweden.  Although we are thrilled to reach these two major milestones in our company's history, we understand that our work is just beginning as we prepare for the start of the Phase II clinical trials of bertilimumab in ulcerative colitis and bullous pemphigoid, and continue the ongoing research in our NanomAb® program.  We are looking forward to executing on these initiatives and to achieving the numerous milestones we have set for ourselves in 2014 and beyond."

In connection with the merger, the Company has issued approximately 9.8 million shares of its common stock in exchange for 100% of the outstanding shares of Immune Pharmaceuticals Ltd, and will exchange the outstanding common stock warrants and options of Immune Pharmaceuticals Ltd. for warrants and options of the Company exercisable for an aggregate of approximately 4.0 million shares of the Company's common stock. The Company's total outstanding common stock was approximately 12.6 million shares immediately following the closing of the merger.  The Company's common stock commenced trading on August 21, 2013 on the Nas
'/>"/>

SOURCE Immune Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Inovio Pharmaceuticals Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
2. EpiCept Stockholders Overwhelmingly Approve Final Conditions to Merger with Immune Pharmaceuticals Ltd.
3. Arisaph Pharmaceuticals Awarded Phase I STTR Grant To Develop Small Molecule Immune Modulators
4. aTyr Pharma Completes $49 Million Financing to Advance a Therapeutic Pipeline for Rare Autoimmune Diseases from a Newly Discovered Class of Proteins, Physiocrines
5. RuiYi et Genor BioPharma collaborent au développement du RYI-008 en Chine, un nouveau traitement contre les maladies auto-immunes et le cancer
6. RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
7. Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
8. MedImmune To Present Seven Posters On Influenza, Respiratory Syncytial Virus At The Annual Pediatric Academic Societies Meeting
9. Immune Pharmaceuticals CEO to Chair BIO International Panel "Can Israel Become the Next Biotech Startup Nation?"
10. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
11. ImmusanTs Epitope-Specific Immunotherapy for Celiac Disease Informs the Potential of Vaccines Against Other Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... NORWALK, Conn. , Oct. 17, 2014 UBM ... , a leading online community and information resource for ... Parkinson disease and Alzheimer disease , with discussions ... Up to 1 million Americans have Parkinson disease , ... muscular dystrophy, or Lou Gehrig disease. Diagnosis can ...
(Date:10/17/2014)... , Oct. 17, 2014 ... the "Research and Development Prospect of China ... Based on the 2013 version, ... government policies about dialysis industry and the relevant ... research about dialysis industry segmentations. Moreover, it analyzes ...
(Date:10/17/2014)... , October 17, 2014 ... Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has announced the ... : North American Automated External Defibrillators ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The report North ... analyzes the market of devices based ...
Breaking Medicine Technology:Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2
... 20, 2011 Reportlinker.com announces that a new ... Rheumatoid Arthritis Market Forecast ... launch of novel oral drugs and reformulations of ... the seven major markets, rising from $12bn in ...
... MADISON, Wis., Sept. 20, 2011 ... the commercial launch of human iCell® Endothelial Cells ... and other life science research. Endothelial ... thus are an important factor of vascular research across ...
Cached Medicine Technology:Rheumatoid Arthritis Market Forecast 2Cellular Dynamics Announces Commercial Launch of iCell® Endothelial Cells for Vascular-Targeted Drug Discovery 2Cellular Dynamics Announces Commercial Launch of iCell® Endothelial Cells for Vascular-Targeted Drug Discovery 3Cellular Dynamics Announces Commercial Launch of iCell® Endothelial Cells for Vascular-Targeted Drug Discovery 4
(Date:10/20/2014)... MA (PRWEB) October 20, 2014 ... sponsoring a booth at the American Foundation for Suicide ... 25th. The AFSP is a not-for-profit organization that hosts ... Net proceeds from these events are used to help ... but education and personal relationships as well. , ...
(Date:10/20/2014)... Indianapolis, IN (PRWEB) October 20, 2014 ... Quick Start, a secure cloud solution that enables ... advantage of the ultimate healthcare-specific customer relationship management ... to meet the unique needs of the healthcare ... healthcare experience for providers and patients by combining ...
(Date:10/20/2014)... Principle Business Enterprises, a family owned ... top-of-the-line absorbent products. The company has recently made ... brand, Tranquility® Premium Protection absorbent products. The company ... its packaging a new look, and is currently working ... the public. , The new website, developed with Thread ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked in ... Every Body Walk! campaign by Kaiser Permanente. ... workers to be more active outside of the workplace. ... the end of September, was a friendly competition between organizations ... Participating companies gave their staff pedometers and each day, for ...
(Date:10/20/2014)... 20, 2014 Unveiled at the Sept. 18 ... Scorecard conservatively estimates member hospital ROI on membership dues at ... The Center provides $12.50 in value to member hospitals. The ... – Member Dues)/Member Dues. , “This is the first ... and we think the methodology is really sound,” said ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4
... new method for creating nanofibers made of proteins, developed ... (NYU-Poly), promises to greatly improve drug delivery methods for ... as well as aid in the regeneration of human ... this same development could point the way to even ...
... Center for Healthy Neighborhoods of Case Western Reserve ... groups on three of the most pressing public ... The three data briefs statistical public health ... prevalence estimates for diabetes, hypertension awareness and obesity ...
... -- Even when fast-food restaurants list calorie counts for menu ... information to make healthy meal choices, researchers report. In ... 200 food items on menu boards from 12 restaurant chains ... often, calorie counts were listed for combo meals or meals ...
... at Moffitt Cancer Center in Tampa, Fla., and colleagues ... prevent resistance to the chemotherapy drug vemurafenib, commonly used ... characterized by a diminished apoptosis (programmed cancer cell death) ... and cell survival is regulated by a family of ...
... National Jewish Health has received a grant for $950,308 ... Colorado,s San Luis Valley with educational materials for patients ... is the most common chronic illness in children and ... days. The San Luis Valley has one of the ...
... of all deaths in the United States are linked to ... inactivity. Despite these causal links, of the $2 trillion spent ... of that is devoted to addressing behavioral and social risk ... in behavioral and social sciences with a new $500,000 grant ...
Cached Medicine News:Health News:Nanofiber breakthrough holds promise for medicine and microprocessors 2Health News:First breakdown of public health data for Cleveland neighborhoods 2Health News:First breakdown of public health data for Cleveland neighborhoods 3Health News:Many Gaps in Fast-Food Nutrition Information 2Health News:Researchers find potential solution to melanoma's resistance to vemurafenib 2Health News:National Jewish Health receives grant to improve care of asthma patients in the San Luis Valley 2Health News:National Jewish Health receives grant to improve care of asthma patients in the San Luis Valley 3Health News:Training grant targets behavioral and social factors linked to health 2Health News:Training grant targets behavioral and social factors linked to health 3
... Diagnostics offers Q Fever IFA Test Kits ... and IgM human antibody responses to Coxiella ... the simultaneous semi-quantitative detection and differentiation of ... Phase II antigens. By providing the two ...
Claes Shielded Retinotomy Scissors, Vertical...
... is intended for qualitatively detecting antibodies to ... The test is indicated for testing persons ... aid in the presumptive laboratory diagnosis of ... for self-testing, and this test is not ...
... test for the detection and semi-quantitation of ... Encephalitis virus (SLE), Western Equine Encephalitis virus ... California Encephalitis/La Crosse virus (CE). Each kit ... spots of SLE, WEE, EEE, and CE ...
Medicine Products: